Inflammation as the Central Integrator of Cardiometabolic and Chronic Disease Pathophysiology
##doi.readerDisplayName##:
https://doi.org/10.64784/146キーワード:
Systemic inflammation、 Chronic disease、 Atherosclerosis、 Cardiovascular risk、 IL-1 beta、 IL-6、 C-reactive protein、 Immunometabolism、 Endothelial dysfunction、 Residual inflammatory risk、 Inflammaging、 Multimorbidity要旨
Systemic low-grade inflammation has emerged as a central biological mechanism underlying the development and progression of major chronic non-communicable diseases. This integrative review analyzes mechanistic, epidemiological, and interventional evidence supporting inflammation as a unifying pathophysiological axis, with particular emphasis on cardiovascular disease. Foundational immunological frameworks describe nonresolving inflammation as a driver of endothelial dysfunction, cytokine amplification, metabolic dysregulation, and tissue remodeling. In atherosclerotic cardiovascular disease, inflammatory signaling within the arterial wall contributes to plaque instability and thrombo-inflammatory activation, and clinical trial data demonstrate that targeted anti-inflammatory therapy can reduce recurrent cardiovascular events in selected populations. Parallel evidence from immunometabolic research links obesity and type 2 diabetes to chronic inflammatory activation, reinforcing the interconnected immune–metabolic–vascular model. The review also addresses inflammaging and multimorbidity, highlighting how sustained inflammatory tone increases vulnerability to cardiometabolic and systemic disease across the lifespan. Translational implications include biomarker-guided risk stratification, recognition of residual inflammatory risk, and integration of lifestyle and pharmacologic strategies aimed at modulating inflammatory burden. From an international perspective, particularly in middle-income countries experiencing epidemiological transition, understanding systemic inflammation as a shared biological substrate may support more integrated prevention and management strategies within internal medicine.
参考文献
Barnes, P. J. (2016). Inflammatory mechanisms in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 138(1), 16–27. https://doi.org/10.1016/j.jaci.2016.05.011
Calder, P. C., Ahluwalia, N., Brouns, F., et al. (2017). Dietary factors and low-grade inflammation in relation to overweight and obesity. British Journal of Nutrition, 106(S3), S5–S78. https://doi.org/10.1017/S0007114511005460
Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867. https://doi.org/10.1038/nature01322
Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 11(2), 98–107. https://doi.org/10.1038/nri2925
Esser, N., Paquot, N., & Scheen, A. J. (2014). Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica, 69(6), 405–412. https://doi.org/10.1179/2295333714Y.0000000047
Franceschi, C., & Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. Journal of Gerontology: Biological Sciences, 69(S1), S4–S9. https://doi.org/10.1093/gerona/glu057
Furman, D., Campisi, J., Verdin, E., et al. (2019). Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 25(12), 1822–1832. https://doi.org/10.1038/s41591-019-0675-0
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899. https://doi.org/10.1016/j.cell.2010.01.025
Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542(7640), 177–185. https://doi.org/10.1038/nature21363
Kotas, M. E., & Medzhitov, R. (2015). Homeostasis, inflammation, and disease susceptibility. Cell, 160(5), 816–827. https://doi.org/10.1016/j.cell.2015.02.010
Libby, P., & Hansson, G. K. (2015). Inflammation and immunity in diseases of the arterial tree. Nature Reviews Immunology, 15(8), 505–516. https://doi.org/10.1038/nri3859
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203), 428–435. https://doi.org/10.1038/nature07201
Minihane, A. M., Vinoy, S., Russell, W. R., et al. (2015). Low-grade inflammation, diet composition, and health. British Journal of Nutrition, 114(7), 999–1012. https://doi.org/10.1017/S0007114515002093
Nathan, C., & Ding, A. (2010). Nonresolving inflammation. Cell, 140(6), 871–882. https://doi.org/10.1016/j.cell.2010.02.029
Pearson, T. A., Mensah, G. A., Alexander, R. W., et al. (2003). Markers of inflammation and cardiovascular disease. Circulation, 107(3), 499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45
Ridker, P. M. (2016). From C-reactive protein to interleukin-6 to interleukin-1. Circulation Research, 118(1), 145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656
Ridker, P. M., Everett, B. M., Thuren, T., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119–1131. https://doi.org/10.1056/NEJMoa1707914
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., et al. (2019). Inhibition of interleukin-1β and reduction in cardiovascular events. Lancet, 393(10171), 1833–1844. https://doi.org/10.1016/S0140-6736(18)32734-5
Saltiel, A. R., & Olefsky, J. M. (2017). Inflammatory mechanisms linking obesity and metabolic disease. Journal of Clinical Investigation, 127(1), 1–4. https://doi.org/10.1172/JCI92035
Tabas, I., & Glass, C. K. (2013). Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science, 339(6116), 166–172. https://doi.org/10.1126/science.1230720
